Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2).
J Oncol Pharm Pract
; 27(5): 1235-1244, 2021 Jul.
Article
in En
| MEDLINE
| ID: mdl-33530866
ABSTRACT
OBJECTIVE:
Breast cancer is responsible for most of the cancer-induced deaths in women around the world. The current review will discuss different approaches of targeting HER2, an epidermal growth factor overexpressed in 30% of breast cancer cases. DATA SOURCES We conducted a search on Pubmed and Scopus databases to find studies relevant to HER2+ breast cancers and targeting HER2 as means of immunotherapy. Out of 1043 articles, 105 studies were included in this review. DATASUMMARY:
As well as the introduction of HER2 and breast cancer subtypes, we discussed various aspects of HER2-targeting immunotherapy including monoclonal antibodies, Antibody-drug conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cells and vaccines.CONCLUSIONS:
Despite several ways of controlling breast cancer, the need to investigate new drugs and approaches seems to be much significant as this cancer still has a heavy burden on people's health and survival.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antineoplastic Agents, Immunological
/
Immunotherapy
Type of study:
Systematic_reviews
Limits:
Female
/
Humans
Language:
En
Journal:
J Oncol Pharm Pract
Journal subject:
FARMACIA
Year:
2021
Type:
Article
Affiliation country:
Iran